Abstract: Biomarkers for sepsis and resulting mortality can be detected by assaying blood samples. Changes in the concentration of the biomarkers can be used to indicate sepsis, risk of sepsis, progression of sepsis, remission from sepsis, and risk of mortality. Changes can be evaluated relative to data sets, natural or synthetic or semisynthetic control samples, or patient samples collected at different time points. Some biomarkers' concentrations are elevated during disease and some are depressed. These are termed informative biomarkers. Some biomarkers are diagnostic in combination with others. Individual biomarkers may be weighted when used in combinations. Biomarkers can be assessed in individual, isolated or assays, in parallel assays, or in single-pot assays.
Type:
Grant
Filed:
May 6, 2010
Date of Patent:
October 4, 2011
Assignee:
Alere San Diego, Inc.
Inventors:
Stephen F. Kingsmore, Serguei J. Lejnine, Mark Driscoll, Velizar T. Tchernev
Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes. Further described are novel properties and approaches for use of probes monitored by light in dynamic recombination environments.
Type:
Grant
Filed:
February 19, 2010
Date of Patent:
October 4, 2011
Assignee:
Alere San Diego, Inc.
Inventors:
Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.
Type:
Grant
Filed:
June 21, 2010
Date of Patent:
September 20, 2011
Assignee:
Alere San Diego, Inc.
Inventors:
Olaf Piepenburg, Derek L. Stemple, Niall A. Armes
Abstract: The present invention provides a system and computer program product for implementing a smart transformer, comprising a processor, and a balancing algorithm residing on the processor, wherein the balancing algorithm is stored on a non-transitory computer readable medium having computer executable program code embodied thereon, the computer executable program code configured to cause the system to monitor and control an electric customer load and generation in order to optimize the performance of a distribution transform wherein the processor receives a plurality of system inputs and uses the balancing algorithm to determine a rating of the transformer and an amount of customer load.
Type:
Grant
Filed:
October 6, 2010
Date of Patent:
September 20, 2011
Assignee:
San Diego Gas & Electric Company
Inventors:
William Vincent Torre, Amanda Louise Myers, Michael James Colburn
Abstract: This disclosure describes three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length.
Type:
Grant
Filed:
June 14, 2010
Date of Patent:
September 13, 2011
Assignee:
Alere San Diego, Inc.
Inventors:
Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
Abstract: The present invention relates generally to methods and compositions for expression of polypeptides or delivery of interfering RNA's in various cell types.
Abstract: Compounds are provided for use with hexokinases that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Type:
Grant
Filed:
May 25, 2007
Date of Patent:
August 30, 2011
Assignee:
Takeda San Diego, Inc.
Inventors:
Sheldon X. Cao, Jun Feng, Stephen L. Gwaltney, David J. Hosfield, Robert J. Skene, Jeffrey A. Stafford, Mingnam Tang
Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.
Type:
Application
Filed:
December 23, 2010
Publication date:
August 25, 2011
Applicant:
Vaccine Research Institute of San Diego
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Disclosed is a stabilized composition of troponin; the stabilized composition can comprise a stabilized composition of troponin I, wherein the troponin I is oxidized, the troponin I can be unbound or the troponin I can be in a complex. Disclosed is a method for improving the recovery of troponin I or T from a surface used in immunoassays.
Abstract: A dual energy x-ray imaging system searches a moving automobile for concealed objects. Dual energy operation is achieved by operating an x-ray source at a constant potential of 100 KV to 150 KV, and alternately switching between two beam filters. The first filter is an atomic element having a high k-edge energy, such as platinum, gold, mercury, thallium, lead, bismuth, and thorium, thereby providing a low-energy spectrum. The second filter provides a high-energy spectrum through beam hardening. The low and high energy beams passing through the automobile are received by an x-ray detector. These detected signals are processed by a digital computer to create a steel suppressed image through logarithmic subtraction. The intensity of the x-ray beam is adjusted as the reciprocal of the measured automobile speed, thereby achieving a consistent radiation level regardless of the automobile motion.
Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
Type:
Grant
Filed:
May 31, 2006
Date of Patent:
April 12, 2011
Assignee:
Vertex Pharmaceuticals (San Diego) LLC
Inventors:
Michael P. Maher, Jesus E. Gonzalez, III
Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
Type:
Application
Filed:
December 1, 2010
Publication date:
March 24, 2011
Applicants:
Takeda San Diego, Inc., Takeda Pharmaceutical Company Limited
Inventors:
Sheldon X. Cao, Jun Feng, Yasuhiro Imaeda, Stephen L. Gwaltney, David J. Hosfield, Nobuyuki Takakura, Mingnam Tang
Abstract: This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length.
Type:
Application
Filed:
June 14, 2010
Publication date:
March 10, 2011
Applicant:
Alere San Diego, Inc.
Inventors:
Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
Abstract: A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.
Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.
Abstract: Systems and methods for treating patients with an anxiety disorder are disclosed. The systems comprise a screen for displaying sets of stimuli, a computer to control the display of stimuli onto the screen during at least one treatment session and the ability for the patient to interact with the screen in response to the displayed stimuli. The interaction of the patient with the system during the treatment session is capable of treating patient anxiety associated with an anxiety disorder, such as social anxiety. Also provided are computer programs capable of being used in the systems and methods of the present invention for treating anxiety.
Type:
Application
Filed:
November 17, 2008
Publication date:
February 3, 2011
Applicant:
San Diego State University Research Foundation